Danoprevir, an HCV NS3/4A protease inhibitor, improves insulin sensitivity in patients with genotype 1 chronic hepatitis C

Gut

Volumn 59, Issue 12, 2010, Pages 1694-1698

  Moucari, Rami ^a   Forestier, Nicole ^b   Larrey, Dominique ^c   Guyader, Dominique ^d   Couzigou, Patrice ^e   Benhamou, Yves ^f   Voitot, Hélène ^a   Vidaud, Michel ^a   Seiwert, Scott ^g   Bradford, Bill ^g   Zeuzem, Stefan ^b   Marcellin, Patrick ^a  

^a BEAUJON HOSPITAL   (France)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c MONTPELLIER UNIVERSITY HOSPITAL   (France)

^d RENNES UNIVERSITY HOSPITAL   (France)

^e BORDEAUX UNIVERSITY HOSPITAL   (France)

^f PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^g Intermune Corp   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; DANOPREVIR; PEGINTERFERON; PLACEBO; RIBAVIRIN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DOUBLE BLIND PROCEDURE; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MALE; PRIORITY JOURNAL; VIRUS LOAD;

ADULT; ANTIVIRAL AGENTS; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INSULIN RESISTANCE; LACTAMS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; RNA, VIRAL; SULFONAMIDES; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 78649817575     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2010.219089     Document Type: Article

References (33)

1. Sheikh MY, Choi J, Qadri I, et al. Hepatitis C virus infection: molecular pathways to metabolic syndrome. Hepatology 2008;47:2127-33.
2. Harrison SA. Insulin resistance among patients with chronic hepatitis C: etiology and impact on treatment. Clin Gastroenterol Hepatol 2008;6:864-76.
3. Camma C, Bruno S, Di Marco V, et al. Insulin resistance is associated with steatosis in non diabetic patients with genotype 1 chronic hepatitis C. Hepatology 2006;43:64-71.
4. Bugianesi E, Marchesini G, Gentilcore E, et al. Fibrosis in genotype 3 chronic hepatitis C and nonalcoholic fatty liver disease: role of insulin resistance and hepatic steatosis. Hepatology 2006;44:1648-55.
5. Conjeevaram HS, Kleiner DE, Everhart JE, et al. Race, insulin resistance and hepatic steatosis in chronic hepatitis C. Hepatology 2007;45:80-7.
6. Bedossa P, Moucari R, Chelbi E, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007;46:380-7.
7. Moucari R, Asselah T, Cazals-Hatem D, et al. Insulin resistance in chronic hepatitis C: association with genotypes 1 and 4, serum HCV RNA level and liver fibrosis. Gastroenterology 2008;134:416-23.
8. Cua IH, Hui JM, Kench JG, et al. Genotype-specific interactions of insulin resistance, steatosis, and fibrosis in chronic hepatitis C. Hepatology 2008;48:723-31.
9. Charlton MR, Pockros PJ, Harrison SA. Impact of obesity on treatment of chronic hepatitis C. Hepatology 2006;43:1177-86.
10. Negro F, Clément S. Impact of obesity, steatosis and insulin resistance on progression and response to therapy of hepatitis C. J Viral Hepat 2009;16:681-8.
11. Romero-Gómez M, Del Mar Viloria M, Andrade RJ, et al. Insulin resistance impairs sustained response rate to peginterferon plus ribavirin in chronic hepatitis C patients. Gastroenterology 2005;128:636-41.
12. Poustchi H, Negro F, Hui J, et al. Insulin resistance and response to therapy in patients infected with chronic hepatitis C virus genotypes 2 and 3. J Hepatol 2008;48:28-34.
13. Moucari R, Ripault MP, Martinot-Peignoux M, et al. Insulin resistance and geographical origin: major predictors of liver fibrosis and response to peginterferon and ribavirin in HCV-4. Gut 2009;58:1662-9.
14. Delgado-Borrego A, Jordan SH, Negre B, et al. Reduction of insulin resistance with effective clearance if hepatitis C infection: results from the HALT-C trial. Clin Gastroenterol Hepatol 2010;8:458-62.
15. Romero-Gómez M, Fernández-Rodríguez CM, Andrade RJ, et al. Effect of sustained virological response to treatment on the incidence of abnormal glucose values in chronic hepatitis C. J Hepatol 2008;48:721-7.
16. Petta S, Cammà C, Di Marco V, et al. Time course of insulin resistance during antiviral therapy in non-diabetic, non-cirrhotic patients with genotype 1 HCV infection. Antivir Ther 2009;14:631-9.
17. Overbeck K, Genné D, Golay A, et al. Pioglitazone in chronic hepatitis C not responding to pegylated interferon alpha and ribavirin. J Hepatol 2008;49:295-8.
18. Romero-Gómez M, Diago M, Andrade RJ, et al. Treatment of insulin resistance with metformin in naïve genotype 1 chronic hepatitis C patients receiving peginterferon alfa-2a plus ribavirin. Hepatology 2009;50:1702-8.
19. Vierling JM, Hamzeh FM, Lentz EL, et al. Virologic and metabolic responses in chronic hepatitis C patients with insulin resistance treated with pioglitazone and peginterferon alfa-2a and ribavirin (abstract). Hepatology 2009;50(Suppl 4):1028A.
20. Vanni E, Abate ML, Gentilcore E, et al. Sites and mechanisms of insulin resistance in nonobese, nondiabetic patients with chronic hepatitis C. Hepatology 2009;50:697-706.
21. Pawlotsky JM, Chevaliez S, McHutchison JG. The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology 2007;132:1979-98.
22. Tai AW, Chung RT. Treatment failure in hepatitis C: mechanisms of non-response. J Hepatol 2009;50:412-20.
23. Hoofnagle JH, Seeff LB. Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med 2006;355:2444-51.
24. Shintani Y, Fujie H, Miyoshi H, et al. Hepatitis C virus infection and diabetes: direct involvement of the virus in the development of insulin resistance. Gastroenterology 2004;126:840-8.
25. Aytug S, Reich D, Sapiro LE, et al. Impaired IRS-1/PI3-kinase signalling in patients with HCV: a mechanism for increased prevalence of type 2 diabetes. Hepatology 2003;38:1384-92.
26. Pazienza V, Clément S, Pugnale P, et al. The hepatitis C virus core protein of genotypes 3a and 1b downregulates insulin receptor substrate 1 through genotype specific mechanisms. Hepatology 2007;45:1164-71.
27. Persico M, Capasso M, Persico E, et al. Suppressor of cytokine signalling 3 (SOCS3) expression and hepatitis C virus-related chronic hepatitis: Insulin resistance and response to antiviral therapy. Hepatology 2007;46:1009-15.
28. Bernsmeier C, Duong FH, Christen V, et al. Virus-induced over-expression of protein phosphatase 2A inhibits insulin signalling in chronic hepatitis C. J Hepatol 2008;49:429-40.
29. Harrison SA. Correlation between insulin resistance and hepatitis C viral load. Hepatology 2006;43:1168.
30. Milner KL, van der Poorten D, Trenell M, et al. Chronic hepatitis C is associated with peripheral rather than hepatic insulin resistance. Gastroenterology 2010;138:932-41.
31. Sanyal AJ, Chand N, Comar K, et al. Hyperinsulinemia blocks the inhibition of hepatitis C virus (HCV) replication by interferon: a potential mechanism for failure of interferon therapy in subjects with HCV and nonalcoholic fatty liver disease (abstract 39). Hepatology 2004;40(Suppl 1):179A.
32. Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939-45.
33. Lin W, Choe WH, Hiasa Y, et al. Hepatitis C virus expression suppresses interferon signaling by degrading STAT-1. Gastroenterology 2005;128:1034-41. (Pubitemid 40523553)